Dupilumab Therapy for EGIDs

Sponsor
Children's Hospital of Fudan University
Study ID
NCT07257835
Status
Recruiting
Apply to this trial

Conditions

  • Eosinophilic Gastrointestinal Disorders (EGIDs)

Eligibility Criteria

Sex
ALL
Age
1 Year - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab - Standard Dose — DRUG
    Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.
  • subcutaneous injection — DEVICE
    Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.

Study Details

This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.

Key Dates

Start date
Jan 1, 2025
Status verified
Nov 2025
Primary completion
Jan 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: The patient is over 1 year old; for those who do not respond to conventional treatments (proton pump

Primary Outcome Measure

Endoscopic response rate [ Time Frame: week12, week26, week52 ]

Central Contacts

Related Studies